-
BioPlus appoints chief strategic officer
ALTAMONTE SPRINGS, Fla. — A former MedfusionRx VP has joined BioPlus as its new chief strategic officer.
In his new role, Russell Gay will provide key leadership for all of the business development at BioPlus, including the strengthening and growth of relationships with payers, physicians, the pharmaceutical industry and various industry partners, BioPlus said.
-
ProStrakan announces U.S. launch of Abstral
BEDMINSTER, N.J. — A drug used to treat pain in cancer patients now is available in the United States.
ProStrakan Group announced Monday the launch of Abstral (fentanyl) sublingual tablets. The tablets, which disintegrate rapidly and are placed under the tongue, treat breakthrough pain, common in one-half to two-thirds of people with cancer-related pain.
The drug, an opioid and controlled substance, only is available through a Food and Drug Administration-mandated REMS program. The FDA approved the drug in January.